Related Experiment Video
Updated: Jun 28, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Thrombophilic gene polymorphisms are risk factors for unexplained infertility
Carolyn B Coulam1, R S Jeyendran
1Pregnancy Success Center and Rinehart Center for Reproductive Medicine, Chicago, Illinois, USA. cbcoulam@aol.com
Fertility and Sterility
|October 22, 2008
Summary
Inherited thrombophilia may increase the risk of recurrent implantation failure. Women with unexplained infertility showed a higher prevalence of MTHFR C677T gene polymorphisms compared to fertile controls.
Area of Science:
- Reproductive Medicine
- Genetics
- Hematology
Background:
- Inherited thrombophilia is a known risk factor for recurrent implantation failure.
- The relationship between thrombophilia, unexplained infertility, and implantation mechanisms requires further investigation.
Purpose of the Study:
- To investigate the prevalence of thrombophilic gene polymorphisms in women with unexplained infertility.
- To determine if specific polymorphisms are associated with unexplained infertility.
Main Methods:
- A case-control study comparing 92 women with unexplained infertility to 60 fertile control women.
- Analysis of nine thrombophilic gene polymorphisms, including MTHFR C677T.
Main Results:
- Women with unexplained infertility exhibited a higher prevalence of MTHFR C677T polymorphisms.
- No significant differences were observed for other tested thrombophilic polymorphisms.
Conclusions:
- The MTHFR C677T polymorphism may be associated with unexplained infertility.
- Further research is needed to elucidate the role of thrombophilia in implantation failure and infertility.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...